Using a fluorescent dye to improve breast-conserving surgery outcomes in breast cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of indocyanine green (ICG), a fluorescent dye, to enhance the localization of non-palpable breast lesions in patients undergoing breast-conserving surgery (BCS) after neoadjuvant chemotherapy. Traditional localization methods have limitations, particularly for patients with larger breasts, and ICG aims to provide a safer and more effective alternative. The study will assess the margin-positive rate using this innovative localization technique, potentially improving surgical outcomes for breast cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The Patient with locally advanced breast cancer who is eligible for breast-conserving surgery after receiving neoadjuvant chemotherapy
* Aged over 18 years old
* ECOG performance status: 0 or 1
* The patients with written informed consent

Exclusion Criteria:

* The patient who requires total mastectomy after receiving neoadjuvant chemotherapy
* The patient with no residual mass on ultrasonography or only with microcalcifications
* Pregnant or lactating patient
* The patient with a disability to understand and provide consent
* The patient with severe allergic history to indocyanine green
* Iodine-sensitive patient

Where it's running

• National Cancer Center
  Goyang-si, Gyeonggi-do, South Korea Recruiting

Study contacts

• Principal investigator: Seeyoun Lee, MD — National Cancer Center, Korea
• Study coordinator: Seeyoun Lee, MD
• Email: seeyoun@ncc.re.kr
• Phone: +82-31-920-1736

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ATUSA 3D automated breast ultrasound for suspicious breast lesions

  This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.

  Recruiting at 2 sites iSono Health, Inc. · Sacramento, California and 1 other locations · NCT07505797

• Prehabilitation plus ongoing exercise and nutrition support for women with breast cancer

  This trial will test whether a short supervised pre-treatment program of high-intensity exercise and personalized nutrition followed by home-based exercise and dietary guidance helps newly diagnosed women with stage 0–III breast cancer recover better and tolerate treatment.

  Recruiting at 2 sites European University Miguel de Cervantes · Valladolid, Valladolid and 1 other locations · NCT07467824

• HandX-assisted endoscopic nipple-sparing mastectomy (ATHENA I)

  This study tests whether a handheld robotic device called HandX can help surgeons safely perform a minimally invasive nipple-sparing mastectomy with immediate implant reconstruction for women having therapeutic or risk-reducing mastectomy.

  Recruiting Mediterraneo Hospital · Glyfada, Attica · NCT07292246

• Capecitabine with or without elacestrant for ER-positive advanced breast cancer

  This trial will try adding elacestrant to capecitabine to see if it helps people with ER-positive, HER2-negative advanced breast cancer that stopped responding to CDK4/6 inhibitors.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07222215

• Radiology-based prediction of HER2 level and T‑DXd benefit in metastatic breast cancer

  This study tests whether patterns in CT or FDG‑PET images can show HER2 level and help predict response to trastuzumab deruxtecan for people with metastatic breast cancer.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07030569

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.